Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis

Next Previous
Trial Profile

Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ponesimod (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms OPTIMUM
  • Sponsors Actelion Pharmaceuticals

Most Recent Events

  • 08 May 2023 Results from NCT02634307 and NCT02425644 , comparing DRF versus PON and DRF versus TERI for clinical and radiological outcomes, published in the CNS Drugs
  • 27 Apr 2023 Results (n=239) assessing the clinical and magnetic resonance imaging (MRI) outcomes in RMS patients at 48 weeks of follow-up after short-term interruption and re-initiation of ponesimod treatment, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
  • 25 Feb 2023 Results of an analysis assessing treatment effects of ponesimod and teriflunomide on regional atrophy by quantifying changes in volume of deep gray matter structures presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top